|
By continuing with your order you confirm that
you have a valid prescription and/or have used this item successfully
in the past.
Manufacutured
by:
Schering
Shipping:
Packaged and
Distributed from China
Similar formulation as Ortho-Novum 777, TriNovum ED, Triphasil, Ortho Tri-cyclen,
Trivora
Description
Uses
Triqular is a progestin (levonorgestrel) and estrogen (ethinyl
estradiol) combination birth control pill used for the prevention of
pregnancy. The ingredients of the medication work by
preventing ovulation (the release of an egg from an ovary) and causing
changes in the mucus of the cervix which make it difficult for sperm to
penetrate and for an egg to implant. This medication may also be taken
to treat acne in women 14 years of age and older or to regulate the
menstrual cycle.
Contents
6 red tablets containing 0.05mg levonorgestrel and 0.03mg
ethinylestradiol
5 white tablets containing 0.075mg levonorgestrel and 0.04mg
ethinylestradiol
10 brown tablets containing 0.125mg levonorgestrel and 0.03mg
ethinylestradiol
Dosage and Administration
1 tablet daily for 21 days starting with the red pills in the pack
on the first day of bleeding - the initial tablet being the
one marked
with "开始" and having the red background. Following completion of the
pack, then take no pills for 7 days, and then begin the next pack.
Changing from other oral
contraceptives
The first tablet of Triquilar should be taken on the first day
immediately after the end of the previous oral contraceptive course.
Additional (non-hormonal) precautions other than the rhythm,
temperature or cervical mucus methods should also be used for the first
14 days when changing product.
Contraindications
Pregnancy, severe disturbances of liver function, jaundice or
persistent itching during a previous pregnancy, Dubin-Johnson syndrome,
Rotor syndrome, previous or existing hepatic tumours, existing or
previous thromboembolic processes in arteries or veins and states which
predispose to such diseases (e.g. disturbances of the clotting system
with a tendency towards thrombosis, certain heart diseases), existing
thrombophlebitis, sickle - cell anaemia, known or suspected carcinoma
of the breast or genital organs or suspected oestrogen-dependent
neoplasia, severe diabetes with vascular changes, disturbances of
lipometabolism, a history of herpes of pregnancy, otosclerosis with
deterioration during pregnancy, undiagnosed vaginal bleeding,
hemiplegic migraine.
Interactions
Some medicines (such as certain antibiotics or anti-convulsants) may
reduce the effectiveness of oral contraceptives.
These include phenylbutazone, griseofulvin, rifampicin, barbiturates,
certain antibiotics, hydantoins. The requirements for oral
antidiabetics or insulin can change. Oral contraceptives may
cause alterations in certain laboratory
estimations. A medicine free period of two months may be required
before some of these parameters return to normal.
Warnings and Precautions
Before starting on Triquilar, a thorough general medical (including
blood pressure measurement, urine test for sugar and, if necessary,
special liver tests) and gynaecological (including breasts and
cytological smear) examination must be conducted to detect any diseases
requiring treatment or risks. The family case history should be
carefully noted. Disturbances of the clotting system must be ruled out
if any members of the family have suffered from thromboembolic diseases
(e.g. deep vein thrombosis, stroke, myocardial infarction) already at a
young age. Pregnancy must be excluded.
Intermenstrual bleeding
Tablet taking should not be interrupted if intermenstrual bleeding
occurs. Slight bleeding will usually stop spontaneously, but if it
persists it can be arrested - as can also intermenstrual bleeding of
menstrual intensity - by the additional administration of 0.02 - 0.04mg
ethinylestradiol daily for 4 - 5 days. This medication should not,
however, be continued beyond the last hormonal tablet of a Triquilar
memo-pack. Should breakthrough bleeding persist or recur, a
thorough examination including curettage is indicated to exclude
organic factors.
Gastro-intestinal upset
Vomiting and diarrhoea may reduce efficacy by preventing full
absorption. Barriers and spermicides should be used until 7 days after
the upset; (mild laxatives do not impair contraceptive action).
Adverse Effects
Nausea, vomiting, abdominal cramps, breakthrough bleeding, breast
changes, changes in menstrual flow, changes in cervical erosion and
cervical secretions, amenorrhoea during and after treatment,
anovulation post treatment, cholestatic jaundice, pruritus, allergic
rash, photosensitivity, poor tolerance of contact lenses, alopecia,
chloasma, erythema multiforme, erythema nodosum, haemorrhagic eruption,
hirsuitism, headache, depressive moods, migraine, dizziness,
drowsiness, changes in appetite, body weight and libido can occur.
The physician should be alert to
the earliest manifestations of
thrombotic disorders and medication should be discontinued immediately
should any of these occur. If there is a sudden, partial or
complete
loss of vision or if there is a sudden onset of proptosis, diplopia or
migraine, medication should be discontinued and examination made. If
examination reveals papilloedema or retinal vascular lesions the
medication should be discontinued. Further reasons for
immediate
discontinuation are immobilisation (e.g. following accidents), onset of
jaundice, onset of anicteric hepatitis, itching of the whole body,
increase in epileptic seizures, significant rise in blood pressure,
pregnancy. Oral contraceptive medication should be discontinued at
least six weeks prior to elective surgery because of the danger of
thrombosis. According to the present state of knowledge, an
association between the use of progestogen-oestrogen combinations and
an increased risk of venous and arterial thromboembolic diseases cannot
be ruled out.
The risk of thrombotic
and cardiac effects from oral contraceptives increases with age and is
aggravated by cigarette smoking.
Under the influence of
oral contraceptives pre-existing uterine fibroids may increase in size.
Patients with conditions such as cardiac or renal
dysfunction, diabetes
or a tendency to diabetes, high blood pressure, varicose veins, a
history of phlebitis, otosclerosis, multiple sclerosis, epilepsy,
migraine, porphyria, tetany or chorea minor require careful observation
whilst on oral contraceptive therapy. Patients
with a history of depression should be carefully observed and the
medication discontinued if serious depression recurs. A
decrease in glucose tolerance occurs in a significant number of
patients on oral contraceptives. Susceptible women may
experience a rise in blood pressure during therapy.
Vanist
Direct can only
sell you this item if it has been prescribed by a health care
professional
Vanist
Direct -- Discount Pricing -- Low Prices Brought Directly To You
-- Discount Pricing -- Vanist Direct
|
